InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175
$13.38 +1.52% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $13.38 +10.03% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 Apr 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue50.0Operating income16.1Net income22.7EPS, diluted0.08Fiscal year 2024Revenue0.0 −100.0%Operating income−50.9Net income−42.3 −286.0%EPS, diluted−2.18Fiscal year 2025Operating income−68.1Net income−60.0EPS, diluted−2.17
FY2023FY2024FY2025
Revenue 50.0 0.0 n/a
Growth −100.0%
Operating income 16.1 −50.9 −68.1
Net income 22.7 −42.3 −60.0
Growth −286.0%
EPS, diluted 0.08 −2.18 −2.17

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin32.2%Net margin45.4%Free cash flow margin37.9%Fiscal year 2024Fiscal year 2025
FY2023FY2024FY2025
Operating margin 32.2% n/a n/a
Net margin 45.4% n/a n/a
Free cash flow margin 37.9% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow19.3Capital expenditure−0.4Free cash flow18.9Fiscal year 2024Operating cash flow−32.8Capital expenditure−0.5Free cash flow−33.4 −276.2%Fiscal year 2025Operating cash flow−55.3Capital expenditure−0.2Free cash flow−55.5
FY2023FY2024FY2025
Operating cash flow 19.3 −32.8 −55.3
Capital expenditure −0.4 −0.5 −0.2
Free cash flow 18.9 −33.4 −55.5
Growth −276.2%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash15.5Shareholders’ equity−67.9Fiscal year 2024Cash21.9Shareholders’ equity198.1Fiscal year 2025Cash75.6Shareholders’ equity261.0
FY2023FY2024FY2025
Cash 15.5 21.9 75.6
Shareholders’ equity −67.9 198.1 261.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
32.2% n/a n/a
46.3% n/a n/a
45.4% n/a n/a
37.9% n/a n/a
Spending
55.2% n/a n/a
12.6% n/a n/a
0.8% n/a n/a
1.9% n/a n/a
Returns
n/a −21.3% −23.0%
17.4% −19.9% −21.7%
Balance and payout
4.4% 6.9% 5.7%